⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 16, 2024

Supplemental Figure 8 from Myosin light chain kinase inhibition potentiates the anti-tumor effects of avapritinib in PDGFRA D842V-mutant gastrointestinal stromal tumor

Ferdinand Rossi Mengyuan Liu Andrew Tieniber Mark S. Etherington Andrew Hanna Gerardo A. Vitiello Nesteene J. Param Kevin Do Laura Wang Cristina R. Antonescu Shan Zeng Jennifer Q. Zhang Ronald P. DeMatteo

View at Publisher

Ask AI

Bookmark

Share

Abstract

Supplemental Figure 8. Relative MYLK mRNA expression by qPCR in GIST PDGFRA D842V PDXs treated with vehicle (Veh) or imatinib (IM) for 2 weeks.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Rossi et al. (2024) studied this question.

synapsesocial.com/papers/68e586b5b6db643587522daa https://doi.org/10.1158/1078-0432.27030499.v1

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplemental Figure 8 from Myosin light chain kinase inhibition potentiates the anti-tumor effects of avapritinib in <i>PDGFRA D842V</i>-mutant gastrointestinal stromal tumor2024
2Supplemental Figure 2 from Myosin light chain kinase inhibition potentiates the anti-tumor effects of avapritinib in <i>PDGFRA D842V</i>-mutant gastrointestinal stromal tumor2024
3Supplemental Figure 2 from Myosin light chain kinase inhibition potentiates the anti-tumor effects of avapritinib in <i>PDGFRA D842V</i>-mutant gastrointestinal stromal tumor2024
4Supplemental Figure 6 from Myosin light chain kinase inhibition potentiates the anti-tumor effects of avapritinib in <i>PDGFRA D842V</i>-mutant gastrointestinal stromal tumor2024
5Supplemental Figure 6 from Myosin light chain kinase inhibition potentiates the anti-tumor effects of avapritinib in <i>PDGFRA D842V</i>-mutant gastrointestinal stromal tumor2024

More related papers

Supplemental Figure 3 from Myosin light chain kinase inhibition potentiates the anti-tumor effects of avapritinib in <i>PDGFRA D842V</i>-mutant gastrointestinal stromal tumor2024
Supplemental Figure 3 from Myosin light chain kinase inhibition potentiates the anti-tumor effects of avapritinib in <i>PDGFRA D842V</i>-mutant gastrointestinal stromal tumor2024
Supplemental Figure 5 from Myosin light chain kinase inhibition potentiates the anti-tumor effects of avapritinib in <i>PDGFRA D842V</i>-mutant gastrointestinal stromal tumor2024